Cellebrite to Report Fourth-Quarter and Fiscal Year 2025 Financial Results on February 11, 2026
TYSONS CORNER, Va. and PETAH TIKVA, Israel, Jan. 21, 2026 /PRNewswire/ --…
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for…
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Company to host conference call and webcast on Tuesday, January 20, 2026…
Bank of America Reports Fourth Quarter 2025 Financial Results
CHARLOTTE, N.C., Jan. 14, 2026 /PRNewswire/ -- Bank of America reported its…
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
— First randomized Phase III trial confirming the efficacy of MET inhibition…
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer
January 11, 2026 09:30 ET | Source: RxSight, Inc. ALISO VIEJO, Calif.,…
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up…
Varonis Announces Date of Fourth Quarter and Full-Year 2025 Financial Results
January 09, 2026 16:05 ET | Source: Varonis Systems, Inc. MIAMI, Jan.…
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
January 04, 2026 16:00 ET | Source: Crinetics Pharmaceuticals, Inc. SAN DIEGO,…
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
January 02, 2026 16:05 ET | Source: Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y.,…
